Skip to content
Peptide research

Ipamorelin

Also known as Ipamoreline · NNC 26-0161 · IPAM
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic five-amino-acid peptide that selectively prompts pulse-like growth hormone release, marketed for anti-aging, muscle, and recovery. Selective GH release and short-term safety have moderate support, but fat-loss and bone claims rest mostly on animal data or theory, so the human case is weak. Only three published human studies exist and it stalled at Phase II. Not an approved US drug; sold mostly as research-grade material of uncertain purity.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Ipamorelin is a synthetic 5-amino-acid peptide that stimulates your body's natural growth hormone release. It stands out from other growth hormone-releasing peptides because of its exceptional selectivity — animal studies found selective growth hormone release; in swine, ACTH and cortisol responses remained similar to GHRH even above 200 times the GH-releasing ED50. This clean hormonal profile, comparable to the body's own growth hormone-releasing hormone (GHRH), makes it one of the most popular peptides in the wellness and anti-aging space.

How it works in the body

Selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells to release growth hormone in a controlled, pulse-like manner. In animal studies it did not significantly raise ACTH or cortisol, unlike other GHRPs.

Research overview

Ipamorelin works by binding to the ghrelin receptor in the hypothalamus and pituitary gland, which reduces the brain's growth hormone-inhibiting signal (somatostatin) and triggers pulsatile growth hormone release that mimics the body's natural rhythm. Growth hormone levels typically peak about 40 minutes after dosing, with a half-life of roughly 2 hours. Its most distinctive feature is that it does not elevate ACTH, cortisol, or prolactin — hormones that other growth hormone-releasing peptides like GHRP-2 and GHRP-6 tend to raise. Clinical studies remain relatively limited compared to other peptides in its class, and it has not been FDA-approved for any indication. Most evidence supporting its use comes from preclinical studies and early-phase human pharmacology trials rather than large randomized controlled trials.

Who researches Ipamorelin?

Commonly researched by

  • People exploring muscle growth and performance

    Researched for potential effects on lean mass, strength, or athletic performance.

  • People researching selective gh release

    One of the primary studied benefits of Ipamorelin.

Important considerations for

  • Those with Active cancer

    High

    Growth hormone elevation may promote tumor growth through IGF-1 pathway.

  • Those with Pituitary tumors

    Absolute

    Directly stimulates the pituitary. Contraindicated with pituitary adenomas.

  • Those with Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen diabetic retinopathy.

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data.

Safety & interactions

Do not use if

  • Pituitary tumors

    Absolute

    Directly stimulates the pituitary. Contraindicated with pituitary adenomas.

  • Active cancer

    High

    Growth hormone elevation may promote tumor growth through IGF-1 pathway.

  • Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen diabetic retinopathy.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • Limited human clinical data (3 published studies)

    Moderate

    Gobburu 1999 Pharm Res doi:10.1023/A:1018955126402; Beck 2014 Int J Colorectal Dis PMID 25331030

  • Long-term safety data lacking

    Moderate

    Beck 2014 Int J Colorectal Dis PMID 25331030 (max ~7-day dosing)

  • Did not advance past Phase II clinical trials

    High

    Beck 2014 Int J Colorectal Dis PMID 25331030 (negative efficacy; development halted)

  • Potential GH-related effects: water retention, joint discomfort

    Moderate

    GH/IGF-1 therapy class effects; Beck 2014 PMID 25331030 (well tolerated short-term, these effects not prominent)

  • Theoretical concerns with prolonged GH/IGF-1 elevation and cancer risk

    Theoretical

    IGF-1/cancer epidemiology (association only); no ipamorelin-specific evidence

Interaction summary(6)

Rated by direction with this peptide

  • Somatostatin analogs (octreotide, lanreotide)

    CautionModerate

    Somatostatin is the endogenous inhibitor of GH secretion, so these agents would directly blunt or abolish ipamorelin's GH-releasing effect (pharmacodynamic antagonism). Mechanistically robust, though not tested clinically with ipamorelin; the effect is loss of efficacy, not a safety hazard.

    GH-axis physiology (somatostatin suppresses somatotroph GH release); mechanism-based, no ipamorelin interaction study

  • GHRH analogs (sermorelin, CJC-1295, tesamorelin)

    SynergisticModerate

    GHRH and ghrelin-receptor secretagogues act through complementary pituitary pathways, producing well-documented synergistic (supra-additive) GH release when combined—the basis of the classic GHRH + GHRP provocative GH test.

    Established GH physiology (GHRH + GH-secretagogue synergy); Raun 1998 PMID 9849822 (ipamorelin characterized alongside GHRH)

  • Insulin and other antidiabetic drugs

    CautionModerate

    GH/IGF-1 elevation is diabetogenic (induces insulin resistance and can raise blood glucose), potentially reducing the effectiveness of insulin or oral hypoglycemics and worsening glycemic control. Extrapolated from GH-class data (e.g., MK-677 human trials); not specifically studied for ipamorelin.

    GH class metabolic effect (e.g., GHS MK-677 human data); mechanism-based

  • Other GH secretagogues (GHRP-2, GHRP-6, hexarelin, MK-677)

    SynergisticModerate

    Using GHS-R1a agonists together gives additive GH release and additive side-effect burden, and repeated high-dose co-administration risks receptor desensitization.

    Shared GHS-R1a mechanism; mechanism-based

  • Glucocorticoids (prednisone, dexamethasone)

    CautionTheoretical

    Chronic glucocorticoids suppress the GH axis and can blunt the GH response to secretagogues; conversely, ipamorelin counteracted glucocorticoid-induced bone-formation loss and muscle-strength loss in rats, so the interaction is mixed and unproven in humans.

    GH-axis physiology; Svensson et al. 2001 Growth Horm IGF Res (ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats — animal data)

  • Levothyroxine / thyroid hormone

    CautionTheoretical

    GH-axis stimulation can increase peripheral T4-to-T3 conversion and lower free T4, theoretically unmasking or worsening hypothyroidism and altering thyroid-replacement requirements. Documented with GH therapy; not studied for ipamorelin.

    GH therapy thyroid-axis effect (class); mechanism-based, not studied for ipamorelin

Known risks(5)

  • Limited human clinical data (3 published studies)

  • Long-term safety data lacking

  • Did not advance past Phase II clinical trials

  • Potential GH-related effects: water retention, joint discomfort

  • Theoretical concerns with prolonged GH/IGF-1 elevation and cancer risk

Drug interactions(3)

  • CJC-1295

    Most common clinical combination. CJC-1295 sustains baseline GH, ipamorelin triggers acute pulses. 3-5x GH vs either alone.

  • GHRP-2/GHRP-6

    All GHS-R agonists.

  • Sermorelin

    GHRH + GHS-R pathways complement each other similarly to CJC-1295 combo

Research & benefits

Evidence base

Evidence Level
Limited Clinical
Total Studies
48
Human Studies
3

PK study in healthy males (1999), Phase II POC for postop ileus (n=114, 2014), Phase II dose-finding bowel resection (n=320). POC well-tolerated but missed primary endpoint (p=0.15). Developed by Novo Nordisk, later licensed to Helsinn, did not advance past Phase II.

Researched for(7)

Rated by confidence in the evidence

  • Selective GH release

    Medium

    Raises GH, with ACTH and cortisol responses similar to GHRH in animal studies.

    Raun 1998 Eur J Endocrinol PMID 9849822 (animal/in vitro selectivity); Gobburu 1999 Pharm Res doi:10.1023/A:1018955126402 (human GH release)

  • Body composition

    Speculative

    Lean-mass and fat-loss effects are inferred from animal growth data and the GH/IGF-1 mechanism.

    Raun 1998 PMID 9849822 (animal growth/weight gain); GH/IGF-1 mechanism

  • Bone growth/density

    Low

    Dose-dependent bone growth in rats, reflecting larger bone size rather than higher density.

    Johansen 1999 Growth Horm IGF Res PMID 10373343 (longitudinal bone growth in rats); Svensson 2000 J Endocrinol PMID 10828840 (BMC increase via larger bone size, not density); Svensson et al. 2001 Growth Horm IGF Res (counteracts glucocorticoid-induced decrease in bone formation in adult rats)

  • Muscle strength

    Speculative

    Rat muscle-tension finding only; related secretagogues showed no human strength gain despite lean-mass gains.

    No direct human ipamorelin strength data; GHS-class mechanism (MK-677 human trials showed lean-mass gain without strength gain)

  • GI motility

    Low

    Positive in rodent gut-motility models, but a human trial found no benefit.

    Venkova 2009 JPET PMID 19289567 (positive rodent POI model); Beck 2014 Int J Colorectal Dis PMID 25331030 (negative human RCT)

  • Anti-emetic

    Speculative

    Ferret data shows reduced chemo weight loss; the anti-emetic effect was specific to anamorelin, not ipamorelin.

    Physiol Behav 2024, 'GHS-R1a agonists anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets; anamorelin also exhibits anti-emetic effects via a central mechanism' (anti-emetic effect specific to anamorelin, not ipamorelin); ghrelin-class mechanism

  • Safety profile

    Medium

    Serious adverse events occurred in the postoperative trial, including two deaths with ipamorelin; causality was unclear. Safety for other injectable routes remains inadequately characterized.

    Beck 2014 Int J Colorectal Dis PMID 25331030; Gobburu 1999 Pharm Res doi:10.1023/A:1018955126402

Benefits(7)

  • Selective GH release

  • Body composition

  • Bone growth/density

  • Muscle strength

  • GI motility

  • Anti-emetic

  • Safety profile

Key studies(5)

  1. Raun K et al.

    Eur J Endocrinol

    1998

    First GHS with GHRH-like selectivity. No ACTH/cortisol at 200x ED50.

  2. Gobburu JV et al.

    Pharm Res

    1999

    Dose-proportional PK, 2-hour half-life, peak GH at 0.67h. No serious AEs.

  3. Johansen PB et al.

    Growth Horm IGF Res

    1999

    Dose-dependent bone growth 42→52 µm/day in adult female rats

  4. Andersen NB et al.

    Growth Horm IGF Res

    2001

    4x periosteal bone formation, increased muscle tension vs glucocorticoid alone

  5. Beck DE et al.

    Int J Colorectal Dis

    2014

    Well-tolerated, safety comparable to placebo. Primary endpoint trend (25.3 vs 32.6h, p=0.15)

What research suggests over time

  • Weeks 2-4

    Practitioner-reported

    Acute GH pulse on injection; subjective sleep and recovery improvements within the first few weeks.

  • Months 2-3

    Mechanistic + clinic data

    Selective GH release, shown in animal studies.

  • Long-term

    Mechanistic

    Limited published long-duration human trials; the selective GH release profile is its main differentiator from older GHRPs.

Regulation & availability

Why researchers look at it

Animal studies found selective GH release, with ACTH and cortisol responses similar to GHRH in swine even above 200 times the GH-releasing ED50, setting it apart from older alternatives like GHRP-2 and GHRP-6. Phase II trials (n=114 and n=320) were well tolerated but narrowly missed primary endpoints for post-surgical bowel recovery. Not FDA-approved. Its withdrawn 503A nomination did not establish compounding eligibility, and ipamorelin acetate remains in 503B Category 2.

Estimated cost
No approved product and no verified reference price
FDA status
Ipamorelin is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in October 2024. Developed by Novo Nordisk and later studied by Helsinn for postoperative ileus through Phase II.
WADA status
Banned — GH secretagogue under prohibited substances
Prescribability
Ipamorelin is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in October 2024.
Availability
Some telehealth platforms offer it, but those offerings do not establish lawful compounding eligibility. Ipamorelin acetate has a withdrawn 503A nomination and remains in 503B Category 2.

International status

  • EU

    Not approved

  • UK

    Not approved

  • US

    Ipamorelin is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in October 2024.

  • Australia

    Schedule 4 via compounding pharmacy with prescription

Regulatory timeline(4)

  1. 1998
    First publishedRaun et al. established selectivity profile
  2. 2014
    Phase II RCTPostoperative ileus trial (n=114). Well-tolerated but missed primary endpoint.
  3. 2023-09
    FDA Category 2Restricted from compounding
  4. 2024-09
    Removed from Category 2Ipamorelin acetate removed after nominator withdrawal

Sources & FAQs

Research sources(5)

Frequently asked questions(4)

How does it differ from GHRP-6/GHRP-2?

In animal studies ipamorelin was selective, with ACTH and cortisol responses similar to GHRH. GHRP-6 also causes strong hunger.

How long to see results?

Sleep/recovery 2-4 weeks. Body composition 4-6 weeks. Full benefits 3-6 months.

Side effects?

Mild: injection site reactions, water retention, flushing, occasional insomnia. Safety comparable to placebo in trials.

Legal in 2026?

A prescription alone does not establish lawful compounding access. No current 503A Category 1 pathway is established, and ipamorelin acetate remains in 503B Category 2. WADA prohibits ipamorelin at all times.